Cialis and Levitra

Vardenafil(Levitra), a phosphodiesterase-5 (PDE-5) inhibitor, has been shown to improve erections in up to 80% of men and increase their ability to complete sexual intercourse with ejaculation, according to a presentation at the XVI annual European Association of Urology (EAU) meeting in Geneva, Switzerland. The study was the first large-scale patient trial of vardenafil(Levitra), which is made by Bayer.

“Vardenafil(Levitra) improved erectile function in these men, regardless of their age, cause, or severity of their problem. This improvement occurred even at the lowest dose of 5 mg,” said Dr. Irwin Goldstein, Boston University School of Medicine, a co-author of the study and a member of the international Vardenafil Study Group. “There was another important finding as well,” continued Goldstein. “In the overall study, vardenafil(Levitra) not only helped most men achieve erections, they also were able to sustain their erections and successfully complete intercourse.”

The analyses involved 580 patients, aged 21-70 years, in stable heterosexual relationships, from 39 treatment centers in the United States, Belgium, France, Germany, the Netherlands, Poland, and South Africa. The patients had experienced difficulty with erectile function of organic, psychogenic, or mixed etiology for an average of 2.8 years. They were randomized into 4 groups and received vardenafil(Levitra) in 5 mg, 10 mg, 20 mg doses, or placebo on demand, but not more than once a day.
Read the rest of this entry »

read comments (0)

The phosphodiesterase type 5 (PDE5) inhibitor vardenafil (Levitra) improves symptoms and digital blood flow, both at room temperature and during a cold-exposure test, in some patients with Raynaud disease, results of a pilot study suggest.

Raynaud disease can be difficult to treat, especially among patients whose disease is secondary to connective tissue diseases, such as systemic sclerosis. In the January 23rd issue of the Archives of Internal Medicine, Dr. Stephan Rosenkranz and colleagues at Universitat zu Koln in Germany suggest that, because PDE5 inhibition is used to treat erectile dysfunction on the basis of its vasodilatory properties, it would be of benefit in patients with Raynaud disease. Read the rest of this entry »

read comments (0)

Treatment with tadalafil in men with erectile dysfunction after radiotherapy for prostatic carcinoma was effective and well tolerated, according to the results of a study reported in the October issue of the International Journal of Radiation Oncology, Biology and Physics.

“Erectile dysfunction after three-dimensional conformal external-beam radiotherapy (3DCRT) for prostatic carcinoma is reported in as many as 64% of those patients,” write Luca Incrocci, MD, PhD, from the Erasmus MC-Daniel den Hoed Cancer Center in Rotterdam, the Netherlands, and colleagues. “The purpose of this study was to determine the efficacy of the oral drug tadalafil (Cialis) in patients with erectile dysfunction after radiotherapy for prostatic carcinoma.” Read the rest of this entry »

read comments (0)

The Effect Of Tadalafil(Cialis) On Psychosocial Outcomes In Swedish Men With Erectile Distress: A Multicentre, Non-Randomised, Open-Label Clinical Study

A multicentre, non-randomised, open-label study assessed whether personal distress caused by erectile dysfunction (ED) affected psychosocial outcomes of tadalafil treatment. Eligible Swedish men at least 18 years old reporting ?3-month history of ED were stratified into two groups (manifest or mild/no distress) based upon a distress question administered at enrolment. Tadalafil 20 mg was taken as needed for 8 weeks. The primary outcome was the difference between the two distress groups in change from baseline in the Psychological and Interpersonal Relationship Scales (PAIRS) spontaneity domain. Secondary outcome measures were PAIRS sexual self-confidence and time concerns domains, Life Satisfaction (LiSat-11) checklist and a Global Assessment of Treatment Response. The study also assessed tolerability. Of 662 men enrolled, 88% had manifest distress and 12% had mild/no distress. Baseline-to-endpoint changes for PAIRS domains were not significantly different between groups. Baseline-to-endpoint changes in LiSat-11 items were not significantly different between groups except for satisfaction with sexual life. Compared with men without ED, below normal baseline satisfaction with partner relationship and family life were normalised at endpoint. Over 90% of men reported improved erection and ability to engage in sexual activity. The most common treatment-emergent adverse events were headache, myalgia, dyspepsia, flushing and back pain. One man discontinued because of myalgia; 630 (95%) completed the study. In conclusion, erectile distress levels vary among patients with ED and distress can affect intra-familiar aspects of life, which may have implications for clinical practise. However, distress does not appear to hinder improvement in both mechanical and psychosocial outcomes of tadalafil treatment.

read comments (0)

Cialis and Levitra - is the source, where you can find articles about brand name and generic Cialis and Levitra.

If your erectile dysfunction is a result of a physical problem, your doctor may prescribe one of the three FDA-approved drugs: Viagra, Cialis, or Levitra.

It can be interesting for you to read information about this drugs.

read comments (0)